Background {#Sec1}
==========

Increasing evidence suggests that type 2 diabetes (T2D) is an independent risk factor for fragility fractures, and the skeleton was recently recognized as another target tissue subject to diabetic complications \[[@CR1]\]. The superposition of the molecular mechanisms that control bone homeostasis and energy metabolism creates a possibility in which T2D and antihyperglycemic therapies may similarly affect the skeleton \[[@CR2], [@CR3]\].

In this context, it has been postulated that dipeptidyl peptidase-4 inhibitors (iDPP-4) may produce positive effects on bone as a result of the regulation of various intestinal hormones, such as glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-2 (GLP-2), which increase bone formation and prevent bone resorption \[[@CR4]--[@CR10]\]. Female mice treated with sitagliptin, an iDPP-4, exhibited significant improvements in the vertebral bone mineral density (BMD) and trabecular architecture \[[@CR11]\]. A meta-analysis that compared 11,880 iDPP4 users with 9175 patients from the control group (placebo or active medications) suggested that iDPP4 may be associated with a 40% reduction in the risk of bone fractures \[[@CR12]\].

Sulfonylureas likely have the lowest impact on bone metabolism among oral antidiabetics \[[@CR2]\]. Gliclazide modified release (MR) is a highly potent and selective sulfonylurea that is considered a reference drug within this class because of its low risk of hypoglycemia compared with other sulfonylureas and its lack of increase in cardiovascular mortality \[[@CR13], [@CR14]\]. To date, there are no prospective randomized studies in humans that have examined the effect of the iDPP-4 vildagliptin with other classes of oral anti-diabetic agents on BMD and biochemical markers of bone remodeling, particularly in postmenopausal women. The comparison of vildagliptin with a sulfonylurea, seemingly neutral for bone metabolism, appears to be a useful approach to investigate the hypothesis that the former medication is also harmless for bone. This study was therefore designed to assess and compare the effects of a 12-month treatment of vildagliptin and gliclazide MR on bone metabolism and BMD in postmenopausal women with uncontrolled T2D.

Methods {#Sec2}
=======

Patients and study design {#Sec3}
-------------------------

This study is part of the BoneGLIC study (registered at Clinical Trials.gov with Number NCT01679899). It is a 12-month, one-center (Curitiba Diabetes Center, Brazil), randomized controlled trial. All study subjects were postmenopausal women diagnosed with T2D treated with metformin, who fulfilled the following inclusion criteria: age ≥40 years old and glycated hemoglobin (HbA1c) ≥6.5% (48 mmol/mol) at randomization. The exclusion criteria included an acute cardiovascular event (cardiac, cerebral or peripheral), chronic dialysis and/or renal transplantation, serum creatinine \>1.5 mg/dL, human immunodeficiency virus infection, severe autoimmune disease, chronic treatment with oral steroids (\>30 consecutive days), current or previous treatment with incretin mimetics (iDPP-4 or GLP-1 receptor agonists), current or previous treatment with pioglitazone or rosiglitazone, body mass index (BMI) \>50 kg/m^2^, HbA1c ≥9%, chronic or alcoholic liver disease, plasma triglycerides \>1000 mg/dL (11.3 mmol/L), serum 25-hidroxi-vitamin D (25-OH-vit.D) \<20 ng/mL, abnormal levels of parathyroid hormone (PTH), serum cortisol, insulin-like growth factor 1 (IGF-1) or growth hormone (GH) and history of previous fragility fracture. Patients were recruited via media outlets, including online and newspaper advertisements, flyers, radio announcements or after a search for T2D treatment at the research center.

The study protocol was approved by the site ethical review committee in agreement with the Declaration of Helsinki. All participating patients provided their written informed consent prior to screening.

Fifty-six postmenopausal women with T2D were enrolled from October 2012 to October 2014. Randomization occurred through the free online software Research Randomizer version 4.0 (<https://www.randomizer.org/>), which randomly generates numbers that indicate the specific group to which the research subject will be allocated \[[@CR15]\]. Randomization and enrollment were performed by the study coordinator, and the medical investigators assigned participants to the intervention. Blinding was implemented when assessing outcomes, in which the staff personal who analyzed the outcomes did not have access to the identification of the patient examined or the group that the individual was allocated.

Vildagliptin (Novartis Pharma AG, Basel, Switzerland) was administered at 50 mg orally twice daily, and the comparator (control) gliclazide MR (Laboratoires Servier, Neuilly sur-Seine, France) was initially administered at 120 mg orally once daily (maximum dose). If the maximum dose of gliclazide MR was not tolerated or was otherwise associated with unacceptable adverse events, a dose reduction to 60 mg once daily was allowed at the discretion of the investigator. After randomization, the treatment with vildagliptin or gliclazide MR was open-label throughout the study. All patients in both groups received a similar orientation for diet and physical activity performed by the same study site nutritionist, with reinforcement throughout the study.

Coincidentally, all subjects randomized were treated with the oral antidiabetic metformin, and drug naïve or insulin-treated subjects were not randomized.

Measurements {#Sec4}
------------

Anthropometric data were recorded at baseline and each study visit by the same investigator.

The primary study outcomes, the biochemical markers of bone turnover, serum carboxy-terminal telopeptide of type 1 collagen (CTX), serum osteocalcin (OC), serum amino-terminal propeptide of procollagen type I (PINP) and urinary amino-terminal telopeptide of type 1 collagen (U-NTX), were measured at baseline and month 6. Samples of U-NTX, CTX, and OC markers were also collected in month 12.

The secondary outcomes included the BMD of the lumbar spine, femoral neck and total hip that were measured at baseline and month 12. The safety secondary variables alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were collected at baseline, months 6 and 12, and calcitonin was assessed at baseline and month 12.

Exploratory variables, including fasting plasma glucose (FPG), postprandial glucose (PPG) and glycated hemoglobin (HbA1c), were assessed at baseline and every three months until the end of the study at month 12.

Venous blood samples were collected between 7:30 and 9:00 a.m. in the fasting state to measure FPG, HbA1c, lipids, ALT, AST, bone formation markers OC, PINP and the bone resorption marker CTX. Samples were left to clot for 30 min and subsequently centrifuged. The serum was frozen and maintained at --70 °C and then unfrozen for the evaluation of bone turnover markers. PPG was collected 2 h after lunch. The second-morning void urine sample was collected to evaluate the bone resorption marker U-NTX (2 mL urine in a sterile screw cap container), and the results were reported in nmol of bone collagen equivalents per mmol creatinine (nmol BCE/mmol creatinine).

FPG and PPG were measured using the hexokinase method. HbA1c was measured via high-pressure liquid chromatography (HPLC). OC, CTX, and PINP were assessed using an electrochemiluminescence assay (Roche Diagnostics, Basel, Switzerland). The OC inter-assay and intra-assay variabilities are 3.2 and 1.2%, respectively (normal range 15.0--46.0 ng/mL for postmenopausal women). The CTX inter-assay and intra-assay variabilities are 7.8 and 3.9%, respectively (normal range 0.106--1.008 ng/mL for postmenopausal women). The PINP inter-assay and intra-assay variabilities are 2.0 and 1.6%, respectively (normal range 16.3--73.9 µg/L for postmenopausal women). U-NTX were measured via enzyme immunoassay (EIA, Grifols Asia Pacific Pte. Ltd, Singapore). The inter-assay and intra-assay variabilities are 17.2 and 8.6%, respectively (normal range 26.0--83.0 nmol BCE/mmol creatinine for postmenopausal women). The BMD was assessed in agreement with the standards of the International Society for Clinical Densitometry (ISCD) via dual-energy X-ray absorptiometry (DXA, Discovery W, Hologic Inc., Marlborough, MA, USA). The short-term in vivo precision error (root-mean-square standard deviation) was 0.027 g/cm^2^ for L1--L4 (1.1%); 0.034 g/cm^2^ for the femoral neck (2.0%) and 0.032 g/cm^2^ (1.6%) for the total hip.

Physical activity (PA) was defined using the WHO concept (available at <http://www.who.int/topics/physical_activity/en/>) as any bodily movement produced by skeletal muscles that requires energy expenditure, and it was qualitatively evaluated as yes or no. The calcium daily intake was estimated by the sum of the dietary and supplemental ingestion.

The safety and tolerability were recorded at each visit by the investigators. Major hypoglycemia was defined as an event that required the assistance of another individual to actively administer glucagon, carbohydrate, or other resuscitative measures. Minor hypoglycemia was defined as an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose ≤70 mg/dL (3.9 mmol/L) or not accompanied by classic symptoms of hypoglycemia but with a measured plasma glucose ≤70 mg/dL. An event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but that was presumably caused by a plasma glucose ≤70 mg/dL was considered minor hypoglycemia.

Statistical analysis {#Sec5}
--------------------

The sample size was calculated to obtain a significant result in at least one of the primary outcomes (difference \>30% in bone remodeling markers). The change in the OC marker was applied for the calculation. Nineteen patients per group were required to provide 80% power and a 0.05% significance level to detect a difference between means of at least 30% among the two treatments. The expected screening failure rate was 30%, and the estimated dropout rate was 8%; thus, 56 patients were planned for enrollment.

The baseline characteristics were summarized based on the dataset of the intention to treat (ITT) population. The key features at baseline were represented, and comparisons among groups were made using Student *t* tests (parametric variables with normal distribution) or Mann--Whitney tests (non-normal distribution). For primary and secondary variables, which were all quantitative and of a normal distribution, Student *t* tests were used for the statistical analysis. The final statistical analysis of the results was performed taking into consideration only the difference between the means of the analyzed parameters in the 6th and 12th months and the baseline value. Statistical analysis was performed using SPSS for Windows (version 20.0; SPSS, Chicago, IL, USA). All inferential statistical tests were conducted at a p \< 0.05 (two-sided). Unless otherwise stated, data are presented as the mean ± standard deviation (SD).

Results {#Sec6}
=======

Fifty-six patients were enrolled between October 2012 and October 2014. There were 14 screening failures. The remaining women were randomly assigned in a 1:1 manner to vildagliptin (n = 21) or gliclazide MR (n = 21) groups, both in addition to their usual treatment for T2D. Five subjects did not complete the study procedures; thus, 37 patients completed the 12-month follow-up, including 19 patients in the vildagliptin group and 18 patients in the gliclazide MR group (Fig. [1](#Fig1){ref-type="fig"}). The trial ended when the last subject included completed the 12-month follow-up.Fig. 1Patient flow chart. *ICF* informed consent form, *AE* adverse event, *AMI* acute myocardial infarction

The baseline clinical characteristics were not statistically different between the treatment groups (Table [1](#Tab1){ref-type="table"}). The physical activity status remained stable throughout the 12-month period in all individuals.Table 1Baseline characteristics and patient dispositionVildagliptin (N = 21)Gliclazide MR (N = 21)p valueAge (years)62.8 ± 6.461 ± 5.30.324Time since menopause (years)14 ± 8.513.1 ± 8.10.740Race, n (%) Caucasian18 (85.7)19 (90.4)NA Black2 (9.5)1(4.8)NA Hispanic or latino1 (4.8)1 (4.8)NAPhysical activity, n (%)9 (42.9)9 (42.9)1.000Calcium intake (mg/day)^a^811 ± 403824 ± 3970.787Metformin daily dose (mg)1640.5 ± 664.21742.9 ± 626.40.610Body weight (kg)77.3 ± 15.782.7 ± 20.10.336BMI (kg/m^2^)31.7 ± 5.833.8 ± 6.70.287Serum calcium (mg/dL)9.3 ± 0.49.3 ± 0.40.661Serum phosphorous (mg/dL)3.7 ± 0.43.8 ± 0.50.512Serum creatinine (mg/dL)0.78 ± 0.150.75 ± 0.110.483Vitamin D (25OH) (mg/dL)34.7 ± 10.134.9 ± 19.80.963Calcitonin (pg/mL)^b^\<2.0\<2.0NAAST (U/L)23.6 ± 9.330.0 ± 13.50.080ALT (U/L)29.5 ± 19.234.8 ± 19.20.373FPG (mg/dL)144.0 ± 22.4146.8 ± 28.50.729PPG (mg/dL)159.4 ± 48.6147.1 ± 54.60.446HbA1c (%)/(mmol/mol)7.35 ± 0.54/57 ± 5.97.32 ± 0.60/56 ± 6.60.851Variables are presented as the mean ± SD*BMI* body mass index, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *FPG* fasting plasma glucose, *PPG* 2-h postprandial plasma glucose, *NA* not applicable^a^ Both dietary and supplementation^b^ Lower limit of detection of the method is 2 pg/mL

The vildagliptin dose was 100 mg/day (50 mg in two daily intakes) for all patients. The gliclazide MR dose achieved was 72.6 ± 21.1 mg in the 6th month and 73.3 ± 25.7 in the 12th month.

The results of the 6 and 12 months of treatment with vildagliptin or gliclazide MR with respect to the investigated variables are listed in Table [2](#Tab2){ref-type="table"}. For the primary variables, which include the levels of bone turnover markers, there was no significant difference between the vildagliptin and gliclazide MR groups when the differences between the values obtained at months 6 and 12 were compared with the baseline.Table 2Baseline values and changes in bone remodeling marker values in vildagliptin and gliclazide MR treatment groupsVariablesVildagliptin (N = 21)Gliclazide MR (N = 21)*p* value (among groups)OC (ng/mL) Baseline12.5 ± 4.210.2 ± 3.50.063 Change from baseline to month 61.0 ± 3.50.5 ± 2.90.622  *p* value\*0.2040.438 Change from baseline to month 12−0.1 ± 2.90.6 ± 3.80.519  *p* value\*0.9300.468PINP (ng/mL) Baseline38.1 ± 11.836.3 ± 14.70.660 Change from baseline to month 62.4 ± 14.9−0.3 ± 8.30.475  *p* value\*0.4620.887CTX (ng/mL) Baseline0.288 ± 0.1390.197 ± 0.0620.013 Change from baseline to month 60.010 ± 0.0710.029 ± 0.0520.355  *p* value\*0.5230.023 Change from baseline to month 120.001 ± 0.1530.008 ± 0.0600.858  *p* value\*0.5630.972U-NTX (nmol/BCE/mmol creatinine) Baseline41.1 ± 16.535.6 ± 14.40.255 Change from baseline to month 68.1 ± 25.9−2.2 ± 16.40.138  *p* value\*0.1670.555 Change from baseline to month 12−1.1 ± 25.8−1.9 ± 19.30.902  *p* value\*0.8540.660Variables are expressed as the mean ± SD*OC* osteocalcin, *PINP* amino-terminal propeptide of procollagen type 1, *CTX* carboxy-terminal telopeptide of type 1 collagen, *U*-*NTX* urinary amino-terminal telopeptide of type 1 collagen\* *p* value after therapy versus baseline

After 6-month treatment, the OC was 13.5 ± 5.5 in the vildagliptin group versus 10.7 ± 2.6 ng/mL in the gliclazide MR group. At the end of treatment (month 12), the values were 12.5 ± 5.2 versus 10.9 ± 4.0 ng/mL, respectively. An analysis of the differences between months 6 and 12 versus baseline indicates that there is no significant difference in the effect of the drugs on this marker (p = 0.623 and p = 0.519 for months 6 and 12, respectively) (Fig. [2](#Fig2){ref-type="fig"}a).Fig. 2Progression of osteocalcin (**a**) and CTX (**b**) serum levels during the 12-month period (*p* values calculated for differences between means in months 6 and 12 versus baseline)

The bone formation marker PINP was analyzed only at baseline and month 6. In month 6, the serum PINP dosage was 41.8 ± 20.6 in the vildagliptin group versus 35.6 ± 15.7 ng/mL in the gliclazide MR group. As shown in Table [2](#Tab2){ref-type="table"}, there was no difference between both medications in their effect on PINP (p = 0.661) for the difference between month 6 and baseline.

At baseline, the CTX values were higher in the vildagliptin group (0.288 ± 0.139 versus 0.197 ± 0.062 ng/mL in the gliclazide MR group, p = 0.013). In month 6, CTX was 0.258 ± 0.159 versus 0.226 ± 0.080 ng/mL, respectively, and, at the 12th month, the CTX values were 0.289 ± 0.140 versus 0.205 ± 0.074 ng/mL, respectively. Despite the significant difference between the groups in the baseline, there was no difference in the effect of the drugs on this marker when we analyzed only the differences between the means in months 6 and 12 versus baseline (p = 0.355 and p = 0.858 for the 6th and 12th months, respectively) (Fig. [2](#Fig2){ref-type="fig"}b).

After a 6-month treatment, the U-NTX levels were 49.2 ± 26.8 in the vildagliptin group versus 33.4 ± 9.8 nmol BCE/mmol creatinine in the gliclazide MR group. At the end of treatment (month 12), the values were 40.1 ± 23.0 versus 33.6 ± 15.2 nmol BCE/mmol creatinine, respectively. There was a significant difference between the groups in the 6th month; however, when the differences between means in months 6 and 12 and baseline were analyzed, there is no significant difference in the effect of the drugs on this marker (p = 0.138 and p = 0.902 for months 6 and 12, respectively).

The secondary variables, including the BMD of the lumbar spine, femoral neck and total hip, did not exhibit significant differences between groups at baseline or month 12 or the difference between the end of the treatment and baseline (Table [3](#Tab3){ref-type="table"}).Table 3Bone mineral density (BMD) of the lumbar spine, femoral neck and total hipVildagliptin N = 19Gliclazide MR N = 18*p* valueMeanStandard deviationMeanStandard deviationBMD of the lumbar spine (g/cm^2^) Baseline0.9560.2120.9720.1210.771 Month 120.9560.2110.9640.1180.880 Difference from baseline0.0000.025−0.0080.0360.434BMD of the femoral neck (g/cm^2^) Baseline0.7770.1610.7910.0920.747 Month 120.7810.1720.8010.1160.659 Difference from baseline0.0040.0550.0110.0330.612BMD of the total hip (g/cm^2^) Baseline0.9230.1440.9340.1080.789 Month 120.9210.1540.9350.1130.743 Difference from baseline−0.0020.0290.0020.0230.648

The fasting glucose reduced 12.5 ± 34.0 mg/dL in month 12 compared with the baseline value in the vildagliptin group. The variation was 31.1 ± 34.6 mg/dL in the gliclazide MR group, and the difference between the groups from the baseline was not significant (p = 0.086).

The postprandial glucose values presented a reduction of 11.1 ± 64.9 mg/dL in month 12 compared with the baseline in the vildagliptin group. The decrease was 28.9 ± 58.0 in the gliclazide MR group (p = 0.354).

HbA1c exhibited a reduction of 0.39 ± 0.92 percentage point in the vildagliptin group versus 0.80 ± 0.92 in the gliclazide MR group when month 12 was compared with the baseline (p = 0.354). The glucose and safety parameters are available in the Additional file [1](#MOESM1){ref-type="media"}.

Discussion {#Sec7}
==========

Our study is the first investigation to show that 1 year of vildagliptin treatment has the same neutral effect as a sulfonylurea on BMD and markers of bone metabolism in postmenopausal women with T2D. Bone safety is currently an extremely relevant topic, and the present study suggests that sulfonylureas and incretin-based therapies do not appear to have an adverse impact on bone metabolism issues as thiazolidinediones or canagliflozin \[[@CR16]--[@CR23]\].

Both bone formation (PINP and osteocalcin) and bone resorption markers (CTX and U-NTX) did not exhibit significant changes over the follow-up period compared with the baseline in both groups, which suggests that both drugs have similar bone metabolism safety profiles. The BMD values corroborate with these findings, as none of the groups gained or lost bone density after 12 months of treatment. Considering that sulfonylureas likely have the lowest impact on bone metabolism among the oral antidiabetics \[[@CR23]\] and are not associated with changes in the risk of fracture \[[@CR2]\], the results of this study suggest that the iDPP-4 vildagliptin has a similar bone metabolism safety profile and presumably does not increase the risk of fracture, as the sulfonylurea gliclazide. Liraglutide, a GLP-1 receptor agonist with similar features as the DPP-4 inhibitors, has previously demonstrated a similar BMD pattern to a sulfonylurea \[[@CR24]\].

Preclinical studies have indicated that the incretin hormones GLP-2 and GIP play a significant role in bone metabolism via the stimulation of bone formation and inhibition of bone resorption \[[@CR4]--[@CR10]\]. Inhibition of the DPP-4 enzyme increases the levels of both GLP-2 and GIP, which suggests that the class of DPP-4 inhibitors, in addition to controlling glucose levels, may positively affect the bone metabolism. The results in rodents are controversial regarding iDDP-4. Sitagliptin demonstrated neutral results concerning the thickness of the cortical bone in ovariectomized mice and an improvement in BMD and trabecular architecture in a comparative study with pioglitazone \[[@CR11], [@CR25]\].

Most studies in humans have demonstrated that the iDDP-4 class has at least a neutral effect on bone metabolism and the risk of fractures \[[@CR26]--[@CR28]\]. A meta-analysis with 11,880 iDDP-4 users suggested a reduction of up to 40% in the risk of fracture \[[@CR12]\]. In contrast, a retrospective population-based cohort study (N = 216,816) demonstrated no different risk of fracture when iDPP-4 users were compared with controls \[[@CR26]\]. Furthermore, a more recent meta-analysis of 62 randomized clinical trials (N = 62,206 patients) demonstrated that iDPP-4 does not affect the risk of fracture compared with placebo or other antidiabetic medications \[[@CR29]\]. None of these meta-analyses or further studies directly examined the effect of vildagliptin with a sulfonylurea. Moreover, no randomized clinical trial has compared the bone effects of an iDPP-4 with the sulfonylurea gliclazide MR, the only drug in the class that is suggested to have a good cardiovascular safety profile \[[@CR14]\]. The few real comparisons between iDPP-4 and sulfonylureas are derived from studies in which fractures were reported as adverse events and the comparison was made with glipizide or glimepiride.[1](#Fn1){ref-type="fn"}

The current study corroborates most previous studies, with the difference in the comparison of an iDDP-4 to an oral antidiabetic class established to be safe in a prospective, randomized, 12-month duration study. Another strength of our study is that it was performed in a population in which fractures and changes in bone metabolism are more evident, namely, postmenopausal women. The presence of T2D for more than 7 years further increases this risk. Moreover, no fracture was identified in any patient during the 12-month treatment.

The study has several limitations that must be recognized. One limitation is the sample size, which was calculated based on the osteocalcin values for postmenopausal women with T2D \[[@CR30]\]. A greater number of individuals analyzed may demonstrate a difference between the treatments. A longer follow-up may also indicate differences in the BMD not identified in our study with 12 months of active treatment. The presence of a previous fragility fracture was one of the exclusion criteria of the study; unfortunately, there are no data on spine X-ray to assess vertebral fracture. Moreover, physical activity was only qualitatively evaluated. An evaluation of the daily physical activity, expressed as metabolic equivalents (METs), would have provided more valuable information.

Recently, an interim result of a phase IV trial demonstrated that canagliflozin, a sodium-glucose transporter-2 inhibitor (iSGLT2), may be associated with an increased risk of atypical fractures \[[@CR31]\]. Thiazolidinediones are a classical example that an antidiabetic treatment may negatively affect bone and increase the fracture risk \[[@CR16]--[@CR18]\]. Taking this finding into consideration, anti-diabetic drugs, such as iDPP4, that do not cause further harm to bone are reassuring. Longer studies that include a greater number of patients are necessary to demonstrate, in a conclusive manner, iDPP-4 effects on bone metabolism and BMD.

Conclusions {#Sec8}
===========

Bone turnover markers and BMD remained unchanged after a 12-month treatment in both groups, which suggests that vildagliptin has the same safety profile as gliclazide MR on bone metabolism.

Additional file {#Sec9}
===============

**Additional file 1: Table S1.** Baseline values and changes in glucose and safety parameters in vildagliptin and gliclazide MR treatments. **Table S2.** Summary and analysis of non-serious adverse events during the study period, divided by treatment group.
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